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Abstract
Proteinuria is a major determinant of adverse renal outcome, and its reduction slows renal progression in glomerular diseases.
However, the optimal target of proteinuria in glomerular diseases is unclear, and discrepancies in the deﬁnition of proteinuria produce
ambiguous ﬁndings. Here we investigated the optimal target of proteinuria by using different deﬁnitions of proteinuria. We analyzed
574 IgA nephropathy (IgAN), 175 membranous nephropathy (MGN), and 177 focal segmental glomerulosclerosis (FSGS) cases from
3 Korean kidney centers. We evaluated the impact of proteinuria on renal outcome with 2 deﬁnitions: time-average proteinuria (TAP)
and time-varying proteinuria (TVP). The endpoint was renal progression, deﬁned as a 50% decline in glomerular ﬁltration rate or end-
stage renal disease. During a median follow-up of 57.3 months, the primary outcome occurred in 54 patients with IgAN, 26 with
MGN, and 30with FSGS.Multivariate Cox regression using TAP indicated that there was a linear association between proteinuria and
risk of renal progression in IgAN. However, moderate proteinuria was not associated with an increased risk of renal progression in
MGN and FSGS. In contrast, the analysis by TVP showed that the risk signiﬁcantly increased in proportion to proteinuria during
follow-up in all 3 diseases. Our ﬁndings suggest that TVP-based model can delineate association between proteinuria and risk of
renal progression better than TAP-based model, considering that TVP reﬂects the dynamic change of proteinuria over time. Thus,
proteinuria reduction to the lowest possible level is required to improve renal outcomes in patients with glomerular diseases.
Abbreviations: CKD = chronic kidney disease, eGFR = estimated glomerular ﬁltration rate, ESRD = end-stage renal disease,
FSGS = focal segmental glomerulosclerosis, IgAN = IgA nephropathy, MGN = membranous nephropathy, TAP = time-average
proteinuria, TVP = time-varying proteinuria, UPCr = urine protein–creatinine ratio.
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Glomerular disease is an important cause of end-stage renal
disease (ESRD)[1] and has a variable clinical course, from a
benign status without any renal impairment to rapid progressionEditor: Jesper Kers.
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1to ESRD. Proteinuria is the hallmark of glomerular damage,
and high urinary protein excretion is known to be related to an
increased risk of renal progression.[8,9] In addition, the level of
proteinuria has been used to monitor responses to treatment, as
the reduction of proteinuria is associated with a decreased risk of
progression of kidney diseases.[10] In this regard, it is important to
reduce the amount of proteinuria to the lowest possible level in
order to prevent the adverse outcomes of glomerular disease.[11]
For example, we and other groups have consistently shown that
proteinuria reduction to a level of<1.0g/day or 1.0g/g creatinine
results in the lowest risk of progression of immunoglobulin A
nephropathy (IgAN).[12–14] However, a complete disappearance
of proteinuria is difﬁcult to achieve, and residual proteinuria
inevitably persists in many patients despite aggressive immuno-
suppressive treatment. In fact, there is no clearly deﬁned target
level of proteinuria reduction in glomerular diseases. Interesting-
ly, the progression of kidney disease seems to differ even at the
same level of proteinuria depending on the type of primary
glomerular disease. Cattran et al[15] evaluated renal progression
in patients with membranous glomerulonephropathy (MGN),
focal segmental glomerulosclerosis (FSGS), and IgAN, and found
discrepant rates of renal function decline in those with similar
proteinuria levels. Notably, different deﬁnitions of proteinuria
have been used in previous studies of glomerular diseases.[15–18]
These include baseline proteinuria, time-average proteinuria
Kee et al. Medicine (2017) 96:44 Medicine(TAP), and time-varying proteinuria (TVP). For variables that
can change over time, measurements of ﬁxed variables at a
certain time point may be inappropriate for assessing their risk
during the whole disease course. In fact, a recent study suggested
that TVP can reﬂect the dynamic alteration of proteinuria over
time, and thus is the optimal parameter for determining the
prognostic effects of proteinuria.[19]
Therefore, the purpose of this study was to investigate the
optimal target for proteinuria in the management of various
glomerular diseases, including IgAN,MGN, and FSGS by using 2
different deﬁnitions of proteinuria: TAP and TVP. In addition, we
evaluated which deﬁnition of proteinuria is more informative for
the risk stratiﬁcation of these glomerular diseases.
2. Materials and methods
2.1. Patient selection
A ﬂowchart depicting the selection of subjects is presented in
Fig. 1. A total of 1416 renal biopsies had been performed in 1384
patients between 2005 and 2013 in 3 Korean kidney centers:
Yonsei University Severance Hospital (n=1003, 70.8%),
International St. Mary’s Hospital (n=113, 8.0%), and National
Health Insurance Corporation Ilsan Hospital (n=300, 21.2%).
All of our subjects were Koreans, and we excluded 490 patients
who met the following criteria: age <18 or >80 years at
presentation (n=19), follow-up duration <6 months (n=179),
secondary causes of glomerular disease including diabetes (n=
172), transplanted kidney biopsies (n=112), or chronic kidney
disease (CKD) stage 5 without dialysis (n=8). Renal biopsies
were performed bymedical judgment of each nephrologist from 3
kidney centers. Second biopsy was performed in 32 patients,
when either a considerable worsening of clinical course or a
change in treatment strategy was considered. In these patients,
data from the ﬁrst biopsy were included in the analysis. Patients
with missing data were also excluded. Therefore, a total of 934
patients with primary glomerular diseases were ﬁnally included in
the analysis (IgAN, n=574; MGN, n=175; FSGS, n=177). The
study was approved by the Institutional Review Board (IRB) of
Yonsei University Health System Clinical Trial Center. Because
the present study is a retrospective observational study and the
study subjects were anonymized, the IRB waived the need for
written consent from the patients.
2.2. Data collection
Baselinedemographicdata including sex, age, systolicbloodpressure
(SBP), diastolic blood pressure (DBP), body mass index, history ofFigure 1. Study population. FSGS= focal segmental glomerulosclerosis, IgAN=
immunoglobulin A nephropathy, MGN=membranous glomerulonephritis.
2hypertension, and laboratory datawere collected at the time of renal
biopsy. Mean arterial pressure (MAP) was determined as the DBP
plus one-third of the pulse pressure. The collected laboratory data
were as follows: white blood cell count, hemoglobin, glucose,
albumin, calcium, phosphate, blood urea nitrogen, creatinine, total
cholesterol, and estimated glomerular ﬁltration rate (eGFR).
Medications such as renin–angiotensin system (RAS) blockers,
corticosteroids, and other immunosuppressants (cyclosporine and
cyclophosphamide) were also investigated. Users of RAS
blockers were deﬁned as patients who received these medications
for≥3months. Immunosuppressive treatmentwith corticosteroid or
other immunosuppressants was considered to treat regardless of the
duration of therapy. Proteinuria during follow-up was assessed by
using the spot urineprotein–creatinine ratio (UPCr), and the eGFRof
each patient was calculated using the Chronic Kidney Disease
EpidemiologyCollaboration (CKD-EPI) equation.[20] TheUPCr and
eGFR values were determined every 3 months.2.3. Deﬁnition
Deﬁnition of various proteinuria metrics is well described
elsewhere.[19] In short, TAP is deﬁned as the average of
proteinuria values measured at each 3-month interval from
renal biopsy to the end of follow-up or occurrence of primary
outcome. Follow-up time is divided into time window of 3-month
and TVP is the value measured each time window. Detailed
description on how to handle time-varying covariates is beyond
the scope of this study and has been published elsewhere.[21,22]2.4. Treatment
As a retrospective design, the management of patients could not
be standardized and fully controlled, but the institutions treated
the patients with glomerular diseases according to general
guideline-based protocol. Intensive conservative therapy, such as
administration of RAS blockers and diet restriction, was
preferentially given for BP control and reduction of proteinuria
in all 3 types of glomerular diseases. For IgAN patients who had
persistent proteinuria >1.0g/g creatinine, corticosteroids were
administered. We generally followed the 6-month corticosteroid
treatment protocol as previously suggested by Pozzi et al.[23] For
MGN patients, the risk of progression was assessed according to
the Kidney Disease Improving Global Outcomes guideline.[24]
Immunosuppression was postponed up to 6 months after the
diagnosis in patients with a low or moderate risk whose serum
creatinine was maintained stably and urinary protein excretion
did not persistently exceed 4g/d declining over 50% of baseline
value during an observation period with antihypertensive and
antiproteinuric therapy. For patients with a high risk or those
with a moderate risk and rapid progression, corticosteroids plus
cyclosporine or cyclophosphamide were initiated. The typical
protocol for high-risk MGN was the Ponticelli regimen, as
previously suggested.[25] Patients with FSGS who had features of
nephrotic syndrome were initially treated with oral prednisolone
at a single dose of 1mgkg1day1, with gradual tapering of
dosage if CR or PR was achieved. Cyclosporine or cyclophos-
phamide was added in cases of frequent relapses, incomplete
responses, or intolerance to corticosteroids.2.5. Study endpoint
The patients were followed up until December 31, 2015. The time
“0” of this study was the time of renal biopsy before initiating
Table 1
Baseline characteristics of the study patients according to the types of glomerular disease.
IgAN MGN FSGS
(n=574) (n=175) (n=177) P
Male, n (%) 300 (52.3) 94 (53.7) 91 (51.4) .917
Age, y 38.5±13.1 55.0±15.1 47.3±17.0 <.001
BMI, kg/m2 23.5±4.3 24.1±3.1 24.2±3.7 .078
SBP, mm Hg 123.1±16.1 125.2±14.5 128.0±15.8 .001
DBP, mm Hg 76.7±11.2 77.7±11.8 79.0±12.2 .056
MAP, mm Hg 92.1±11.8 93.0±13.2 95.4±11.9 .008
Follow-up duration, mo 61.3±29.7 50.7±33.2 54.0±33.2 <.001
Hypertension, n (%) 176 (30.7) 80 (45.7) 90 (50.8) <.001
Cardiovascular diseases, n (%) 15 (2.6) 7 (4.0) 9 (5.1) .242
Nephrotic syndrome, n (%) 63 (11.0) 118 (67.4) 70 (39.5) <.001
Treatment
RASB, n (%) 479 (83.4) 164 (93.7) 162 (91.5) <.001
Corticosteroid, n (%) 106 (18.5) 93 (53.1) 63 (35.6) <.001
Other immunosuppressants, n (%) 23 (4.0) 59 (33.7) 31 (17.5) <.001
Laboratory data
WBC, 103/mL 7.4±2.4 7.6±2.6 8.1±3.7 .018
Hemoglobin, g/dL 13.0±1.6 12.8±1.9 12.9±2.0 .417
Albumin, g/dL 4.0±0.6 2.9±0.8 3.5±1.0 <.001
Calcium, mg/dL 9.0±0.5 8.4±0.6 8.8±0.7 <.001
Phosphate, mg/dL 3.8±0.6 3.9±0.6 4.0±0.7 .001
BUN, mg/dL 15.2±7.1 16.8±9.1 18.8±10.1 <.001
Creatinine, mg/dL 1.05±0.48 1.02±0.50 1.19±0.67 .002
Total cholesterol, g/dL 186.3±44.1 230.5±74.4 228.6±86.7 <.001
UPCr, g/g 1.42±1.84 5.37±4.17 4.26±5.45 <.001
eGFR, mLmin11.73m2 88.2±32.9 87.7±36.9 79.7±40.8 .019
eGFR stage, mLmin11.73m2
≥90, n (%) 255 (44.4) 79 (45.1) 59 (33.3) .024
60–89.9, n (%) 215 (37.5) 59 (33.7) 62 (35.0) .618
30–59.9, n (%) 88 (15.3) 30 (17.1) 42 (23.7) .035
15–29.9, n (%) 16 (2.8) 7 (4.0) 14 (7.9) .010
All data are expressed as mean± standard deviation. RASB includes angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers. Other immunosuppressants include cyclosporine and/or
cyclophosphamide.
BMI=body mass index, BUN=blood urea nitrogen, DBP=diastolic blood pressure, eGFR= estimated glomerular ﬁltration rate, FSGS= focal segmental glomerulosclerosis, IgAN= immunoglobulin A
nephropathy, MAP=mean arterial pressure, MGN=membranous glomerulonephritis, RASB= renin–angiotensin system blocker, SBP= systolic blood pressure, UPCr=urine protein/creatinine, WBC=whole
blood cell.
Kee et al. Medicine (2017) 96:44 www.md-journal.comtreatment. The study primary endpoint was a sustained decrease
in eGFR of>50% for at least 2 consecutive measurements, or the
onset of ESRD. ESRD was deﬁned as the initiation of chronic
dialysis, or kidney transplantation. Renal survival times were
deﬁned as the duration from the time of biopsy to the last follow-
up.2.6. Statistical analysis
Normally distributed variables are expressed as mean± standard
deviation and compared by using 1-way analysis of variance.
Categorical variables were compared by the Chi-square test, as
required. Cox proportional hazard models were used to examine
the associations of TAP and TVP with renal progression. All
analyses were stratiﬁed by glomerulonephritis type. The
association of TAP grouped by 4 categories with renal outcome
was estimated. In time-varying models, proteinuria and BP were
calculated and updated at each quarter during the entire follow-
up, to assess the short-term associations between proteinuria and
renal outcome.[19,21,26] Clinically relevant factors or signiﬁcantly
associated variables with renal outcomes in univariate analyses
were adjusted in multivariate models. The results are expressed as
a hazard ratio and 95% conﬁdential interval. Death that
occurred before reaching primary outcome was treated as a
competing risk. The discriminatory ability of each proteinuria3metric was compared by C-statistics. The rate of renal function
decline per year was assessed by using the slope of eGFR obtained
from a generalized linear mixed model. Data were analyzed by
using SPSS version 23 software (SPSS, Chicago, IL) and SAS
version 9.2 (SAS, Inc., Cary, NC). All P-values were 2-tailed, and
a value of <.05 was considered statistically signiﬁcant.3. Results
3.1. Patient characteristics according to types
of glomerular disease
The patient characteristics according to types of glomerular
disease are shown in Table 1. Patients with MGN (55.0±15.1
years) were older than those with IgAN (38.5±13.1 years) or
FSGS (47.3±17.0 years). There was no sex difference among the
groups. Blood pressure (BP) was signiﬁcantly higher and the
presence of hypertension was more common in patients with
FSGS than in the other 2 groups. In contrast, immunosuppressant
therapy was more commonly used in patients with MGN and
FSGS than in those with IgAN. Themean follow-up duration was
61.3, 50.7, and 54.0 months for IgAN, MGN, and FSGS,
respectively. The baseline UPCr was signiﬁcantly higher in
patients with MGN (5.37±4.17g/g) and FSGS (4.26±5.45g/g)
than in those with IgAN (1.42±1.84g/g), whereas the baseline
Table 2
Renal outcomes according to 4 categories of time-average proteinuria in 3 types of glomerular disease.
TAP, g/g
IgAN MGN FSGS
<1.0 1–1.99 2–2.99 ≥3.0 <1.0 1–1.99 2–2.99 ≥3.0 <1.0 1–1.99 2–2.99 ≥3.0
(n=417) (n=106) (n=30) (n=21) (n=46) (n=38) (n=29) (n=39) (n=72) (n=51) (n=17) (n=40)
eGFR decline>50% 9 (2.2) 17 (16.0) 13 (43.3) 15 (71.4) 1 (2.2) 3 (7.9) 3 (8.3) 19 (34.5) 1 (1.4) 5 (9.8) 5 (31.3) 19 (48.7)
ESRD 3 (0.7) 7 (6.6) 9 (30.0) 9 (42.9) 0 (0.0) 0 (0.0) 0 (0.0) 8 (20.5) 0 (0.0) 0 (0.0) 2 (12.5) 11 (28.2)
Values are given as number (percentage). Composite outcomes includes a sustained decreased in eGFR of >50% or onset of ESRD.
eGFR= estimated glomerular ﬁltration rate, ESRD= end-stage renal disease, FSGS= focal segmental glomerulosclerosis, IgAN= immunoglobulin A nephropathy, MGN=membranous nephropathy, TAP= time-
average proteinuria.
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mLmin11.73m2) and MGN (87.7±36.9mLmin11.73m2)
than in those with FSGS (79.7±40.8mLmin11.73m2).
We analyzed 574 patients with IgAN, 175 with MGN, and
177 with FSGS. All patients were categorized into 4 groups
according to TAP (<1.0, 1.0–1.99, 2.0–2.99, and ≥3.0g/g). In
patients with IgAN, SBP, and MAP showed an increasing
tendency as TAP increased (P for trend= .049 and .043),
whereas there was no difference in these variables between the
TAP groups in patients withMGN (P for trend= .437 and .054)
and FSGS (P for trend= .321 and .331). Patients with higher
TAP tended to have lower levels of eGFR at the time of biopsy
and serum albumin in IgAN (all P for trend<.001) and FSGS (P
for trend= .043 and <.001). In addition, these patients were
more commonly treated with immunosuppressive agents than
thosewith lower TAP (P< .001 for IgANand FSGS, P= .011 for
MGN). The detailed descriptions of baseline characteristics
according to the 4 categories of TAP in each group of
glomerular disease are presented in Supplemental Table S1,
http://links.lww.com/MD/B929.3.2. Renal outcomes according to 4 categories of TAP
Table 2 shows the renal outcomes of the study patients according
to TAP in each type of glomerular disease. Among 926 patients,Figure 2. Kaplan–Meier renal survival curves based on 4 categories of tim
immunoglobulin A nephropathy, MGN=membranous glomerulonephritis.
4primary outcome occurred in 110 (11.9%) patients (54 [9.4%]
with IgAN, 26 [14.9%] with MGN, and 30 [16.9%] with FSGS)
during a median follow-up duration of 57.3 (6.2–127.6) months.
No patients progressed to ESRD before reaching a 50%decline in
eGFR. There were graded increases in the development of the
primary outcome as TAP increased in all types of glomerular
disease. For example, in the IgAN group, 9 (2.2%), 17 (16.0%),
13 (43.3%), and 15 (71.4%) patients with TAP of <1.0, 1.0 to
1.99, 2.0 to 2.99, and ≥3.0g/g reached a 50% decline in eGFR or
ESRD (P= .001). Similar patterns were observed in patients with
MGN and FSGS. Kaplan–Meier curves in IgAN patients also
showed that the renal-event-free survival was signiﬁcantly
decreased in groups with a higher TAP. However, in MGN
patients with TAP of 1.0 to 1.99 and 2.0 to 2.99g/g, renal
survival was similar to those with TAP of<1.0g/g, whereas it was
markedly decreased in those with TAP of ≥3.0g/g. Similarly, the
renal survival rate did not differ between FSGS patients with TAP
of 1.0 to 1.99g/g and those with TAP of <1.0g/g (Fig. 2).
3.3. Optimal target level of proteinuria assessed according
to TAP and TVP
To determine the association between the risk for renal
progression and the level of proteinuria, 2 different deﬁnitions
of proteinuria were used in the Cox proportional hazard models.e-average proteinuria. FSGS= focal segmental glomerulosclerosis, IgAN=
Table 3
Association of TAP and TVP with kidney disease progression.
IgAN MGN FSGS
Proteinuria level, g/g HR (95% CI) P HR (95% CI) P HR (95% CI) P
Model 1
TAP model
<1.00 1.00 — 1.00 — 1.00 —
1.00–1.99 7.51 (3.35–16.86) <.001 3.95 (0.41–38.00) .235 7.16 (0.84–24.61) .072
2.00–2.99 23.94 (10.21–56.11) <.001 4.66 (0.48–44.85) .183 29.37 (3.43–89.41) .002
≥3.00 64.67 (28.21–98.21) <.001 27.04 (3.59–84.23) .001 68.29 (9.12–98.77) <.001
TVP model
<1.00 1.00 — 1.00 — 1.00 —
1.00–1.99 4.09 (3.49–4.78) <.001 2.47 (1.83–3.33) <.001 2.77 (2.03–3.79) <.001
2.00–2.99 6.61 (5.43–8.07) <.001 6.63 (4.99–8.80) <.001 7.06 (5.22–9.55) <.001
≥3.00 12.49 (10.44–14.95) <.001 7.70 (6.01–9.86) <.001 8.63 (6.65–11.20) <.001
Model 2
TAP model
<1.00 1.00 — 1.00 — 1.00 —
1.00–1.99 6.72 (2.96–15.25) <.001 4.63 (2.47–25.99) .191 6.43 (1.12–13.21) .093
2.00–2.99 16.39 (6.69–40.16) <.001 5.09 (3.52–30.28) .163 24.65 (4.21–66.87) .004
≥3.00 30.84 (13.04–72.95) <.001 21.35 (2.73–75.89) .004 55.97 (14.21–97.21) <.001
TVP model
<1.00 1.00 — 1.00 — 1.00 —
1.00–1.99 2.99 (2.56–3.51) <.001 1.83 (1.35–2.49) <.001 2.18 (1.58–3.00) <.001
2.00–2.99 4.72 (3.86–5.76) <.001 4.21 (3.15–5.64) <.001 4.72 (3.46–6.45) <.001
≥3.00 6.05 (5.02–7.29) <.001 4.56 (3.51–5.92) <.001 5.13 (3.89–6.76) <.001
Note: Adjustments in model 1: unadjusted; model 2: age, sex, mean arterial pressure, steroid and immunosuppressant use, and baseline estimated glomerular ﬁltration rate.
CI= conﬁdence interval, FSGS= focal segmental glomerulosclerosis, HR=hazard ratio, IgAN= immunoglobulin A nephropathy, MGN=membranous nephropathy, TAP= time-averaged proteinuria, TVP= time-
varying proteinuria.
Kee et al. Medicine (2017) 96:44 www.md-journal.comTable 3 presents both unadjusted and adjusted Cox models with
TAP and TVP. We adjusted factors that showed either signiﬁcant
association with renal outcome in univariate analyses or well-
established factors related to renal outcome. In time-varying TVP
models, time-varying MAPs calculated at each quarter over the
entire follow-up period were used for adjustment. Patients with
TAP or TVP<1.0g/g were set as reference group in all Cox
analyses. In the analyses with TAP, the risk of renal progression
signiﬁcantly increased in groups with higher TAP. In particular,
IgAN patients with TAP<1.0g/g had the lowest risk of renal
progression, as compared with those with TAP≥1.0g/g. The
HRs for reaching the primary outcome were 6.72 (95%CI: 2.96–Figure 3. Risks for renal progression based on 4 categories of time-average prote
mean arterial pressure, steroid and immunosuppressant use, and baseline estima
glomerulosclerosis, HR=hazard ratio, IgAN= immunoglobulin A nephropathy, MG
515.25, P< .001), 16.39 (95% CI: 6.69–40.16, P< .001), and
30.84 (95% CI: 13.04–72.95, P< .001) in patients with TAP of
1.0 to 1.99, 2.0 to 2.99, and ≥3.0g/g, respectively. Similar
associations were observed in patients with MGN and FSGS.
However, in these patients with moderate proteinuria levels of
1.0 to 2.99g/g, the risk of renal progression was not signiﬁcantly
greater than in those with TAP<1.0g/g. In MGN patients with
TAP of 1.0 to 1.99 (HR 4.63, 95%CI: 2.47–25.99, P= .191) and
2.0 to 2.99g/g (HR 5.09, 95% CI: 3.52–30.28, P= .163), and in
FSGS patients with TAP of 1.0 to 1.99g/g (HR 6.43, 95% CI:
1.12–13.12, P= .093), the risk of renal progression did not differ
from those with TAP<1.0g/g (Fig. 3). We conﬁrmed theseinuria (reference group: TAP<1.0g/g). All variables were adjusted for age, sex,
ted glomerular ﬁltration rate. CI=conﬁdential interval, FSGS= focal segmental
N=membranous glomerulonephritis, TAP= time-average proteinuria.
Figure 4. Risks for renal progression based on 4 categories of time-varying proteinuria (reference group: TVP<1.0g/g). All variables were adjusted for age, sex,
mean arterial pressure, steroid and immunosuppressant use, and baseline estimated glomerular ﬁltration rate. CI=conﬁdential interval, FSGS= focal segmental
glomerulosclerosis, HR=hazard ratio, IgAN= immunoglobulin A nephropathy, MGN=membranous glomerulonephritis, TVP= time-varying proteinuria.
Kee et al. Medicine (2017) 96:44 Medicineassociations by comparing the rates of renal function decline
among the 4 TAP groups. In patients with IgAN, those with TAP
of 1.0 to 1.99g/g (0.59±0.24mLmin11.73m2) had a faster
decline in eGFR than those with TAP<1.0g/g (0.42±0.24mL
min11.73m2, P< .001). However, in MGN and FSGS
patients, there was no difference in the rates of eGFR decline
between those with TAP of 1.0 to 1.99g/g and those with TAP<
1.0g/g (Supplementary Table S2, http://links.lww.com/MD/
B929).
Next, we applied time-varying Cox models in which protein-
uria and BP were treated as time-varying covariates (Fig. 4). As in
the TAP-based analyses, in patients with IgAN, there were
signiﬁcantly graded increases in the risk of renal progression in
higher TVP groups. The HRs for developing the primary
outcome in patients with IgAN were 2.99 (95% CI: 2.56–3.51,
P< .001), 4.72 (95% CI: 3.86–5.76, P< .001), and 6.05 (95%
CI: 5.02–7.29, P< .001) for patients with TVP of 1.0 to 1.99, 2.0
to 2.99, and 3.0g/g, respectively. In contrast to the analyses with
TAP, the risk of renal progression in MGN and FSGS patients
with moderate proteinuria levels of 1.0 to 2.99g/g wasFigure 5. Kaplan–Meier renal survival curves based on 4 categories of tim
immunoglobulin A nephropathy, MGN=membranous glomerulonephritis.
6signiﬁcantly increased as compared with those with TVP of
<1.0g/g. In particular, MGNpatients with TVP of 1.0 to 1.99g/g
had a 1.8-fold increased risk of reaching the primary outcome
(95% CI: 1.40–2.57, P< .001). In addition, FSGS patients with
TVP of 1.0 to 1.99g/g were also signiﬁcantly associated with an
increased risk of developing the primary outcome (HR 2.18, 95%
CI: 1.58–3.00, P< .001). Kaplan–Meier curves also conﬁrmed
these associations. The renal survival rates were signiﬁcantly
decreased in patients with TVP of 1.0 to 1.99g/g compared with
those with TVP<1.0g/g in all 3 groups of glomerular disease
(Fig. 5). In additional analyses with TAP and TVP normalized to
body surface area, there was no difference in the overall results
and there was no improvement in predictive ability (Supplemen-
tary Table S3, http://links.lww.com/MD/B929).
3.4. Additive prognostic value of proteinuria metrics for
renal outcome prediction
To conﬁrm the validity of TVP and TAP as a useful biomarker,
we compared C-statistics between TVP-based and TAP-basede-varying proteinuria. FSGS= focal segmental glomerulosclerosis, IgAN=
Table 4
Comparing the prognostic value for prediction of renal outcomes according to TAP and TVP.
C-statistic (95% CI) DC-statistics (95% CI) P
IgAN
TAP model 0.900 (0.883–0.917) 0.0218 (0.0153–0.0284) <.001
TVP model 0.922 (0.909–0.936)
FSGS
TAP model 0.829 (0.803–0.855) 0.0329 (0.0152–0.0506) <.001
TVP model 0.862 (0.831–0.893)
MGN
TAP model 0.832 (0.784–0.880) 0.0415 (0.0275–0.0555) <.001
TVP model 0.873 (0.849–0.897)
CI= conﬁdence interval, FSGS= focal segmental glomerulosclerosis, IgAN= immunoglobulin A nephropathy, MGN=membranous nephropathy, TAP= time-averaged proteinuria, TVP= time-varying proteinuria.
Kee et al. Medicine (2017) 96:44 www.md-journal.commultivariate Cox regression models. All DC-statistics of TVP-
based models were signiﬁcantly higher than those of TAP-based
models (Table 4). This ﬁnding suggested that TVP predicted renal
outcome better than TAP.4. Discussion
In this study, we evaluated the optimal target level of proteinuria
in patients with the 3 most common types of glomerular disease
using 2 different deﬁnitions of proteinuria. In IgAN, both TAP-
and TVP-based analyses indicated that patients with proteinuria
<1.0g/g were at the lowest risk of renal progression than those
with proteinuria ≥1.0g/g. However, in the MGN and FSGS
groups, patients with moderate proteinuria levels of 1.0 to 2.99g/
g were not associated with the development of adverse renal
outcome when analyzed using TAP. Interestingly, by using time-
varying Cox models, we clearly showed that the risk of renal
progression was minimized when proteinuria was decreased to
<1.0g/g in patients with MGN and FSGS. Thus, by using TVP,
this study substantiated the importance of proteinuria reduction
in themanagement of various glomerular diseases, supporting the
concept of “the lower, the better”.
Glomerular disease is the third most common cause of ESRD
worldwide. IgAN, MGN, and FSGS are the most frequently
diagnosed types of glomerular disease, and can progress to ESRD
unless complete remission (CR) is achieved.[27] Similar to other
kidney diseases, baseline eGFR, pathologic features, response to
therapy, and persistent proteinuria are strongly associated with
renal progression in patients with glomerular disease.[28–30] In
particular, sustained proteinuria correlates well with adverse
renal outcomes in these patients, and the degree of proteinuria
has been used to monitor therapeutic response and to predict
patient outcome.[8,31,32] Therefore, proteinuria reduction should
undoubtedly be incorporated into the treatment strategies to
prevent the renal progression. However, complete disappearance
of proteinuria does not occur in all patients and residual
proteinuria persists in many patients despite the proper use of
immunosuppressive agents. In fact, CR is achieved in only 30%
to 70% of patients with MGN[33,34] and in 20% to 30% of
patients with FSGS.[35–37] To date, the relationship between the
risks of residual proteinuria and future outcome has not yet been
clariﬁed.
In this regard, previous ﬁndings indicating the importance of
achieving partial remission (PR) in MGN and FSGS should be
considered. The serial studies demonstrated that patients who
attained at least PR had better renal survival than those who had
no remission; however, patients with CR had the best
survival.[17,38] Nevertheless, these studies did not investigate7the optimal level of proteinuria for preventing renal progression.
Only 1 study thus far has evaluated this issue. In a study by
Cattran et al,[15] proteinuria of 1.0 to 2.99g1.73m2day1 was
not associated with deterioration of kidney function compared
with proteinuria of 0.5 to 1.0g1.73m2day1 in MGN and
FSGS, whereas the risk of progression started to increase from
proteinuria of>1.0g1.73m2day1 in IgAN. In particular, there
was no difference in the rate of renal function decline between
MGN patients with proteinuria 3.0 to 5.0g1.73m2day1 and
those with proteinuria of 0.5 to 1.0g1.73m2day1. According
to this ﬁnding, the target level of proteinuria seems to differ
depending on the type of glomerular disease. However, the
ﬁnding should be interpreted with caution because TAP was used
in the study. In fact, baseline proteinuria and TAP have been
criticized because these parameters cannot capture longitudinal
changes in proteinuria over time. To overcome this limitation of
ﬁxed covariates, many epidemiologic studies have recently
utilized a time-varying Cox model. By calculating the weighted
average of all the time-window-speciﬁc HRs or risk ratios, this
model enables carrying out more precise risk assessments
particularly when the covariates are highly variable during
follow-up. Barbour et al recognized the strength of TVP and
analyzed the renal outcome in 1351 adults with IgAN, MGN,
and FSGS, by using various deﬁnitions of proteinuria. They
found that TVP best accounted for the prognostic effects of
proteinuria over time, whereas biased results were produced by
other metrics up to 30.3%.[19] Considering these strengths and
shortcomings of the different deﬁnitions of proteinuria, we
sought to estimate optimal target level of proteinuria to delay
renal progression in 3 glomerular diseases by applying both TAP
and TVP. In the analysis with TAP, patients with IgAN had an
increased risk for renal progression in proportion to the
increasing level of proteinuria during treatment, even at a
proteinuria level of 1.0 to 2.0g/g, whereas renal progression was
not observed in patients with MGN or FSGS having proteinuria
level up to 3.0g/g. In contrast, TVP-based analyses clearly
showed that evenmoderately increased proteinuria of 1.0 to 2.99
g/g was signiﬁcantly associated with a markedly increased risk of
renal progression, suggesting that the target proteinuria level
should be lowered to <1.0g/g in all 3 glomerular diseases.
Because TVP can overcome the shortcoming of baseline
proteinuria and TAP which are unable to reﬂect the high
variability of proteinuria during follow-up, we believe that TVP-
based analysis is the ideal method to assess the risk of being
persistently exposed to proteinuria, as suggested by Barbour
et al.[19] It may be difﬁcult to apply this method to clinical practice
immediately, as it requires multiple measurements during
longitudinal follow-up period. However, by doing this, TVP
Kee et al. Medicine (2017) 96:44 Medicinemetric can be helpful in determining an optimal level of
proteinuria target to achieve the best clinical outcomes.
Nevertheless, well-designed randomized controlled trials are
recommended to solve such complex issue.
This study has several limitations. First, we could not analyze
whether further reduction of proteinuria to <0.5g/g would be
more helpful for improving renal outcomes. A Chinese cohort
study by Le et al showed that IgAN patients with TAP of 0.5 to
1.0g/day had an increased risk of renal progression compared
with those with TAP of <0.5g/day. In line with this ﬁnding, our
previous study also showed a faster decline rate of eGFR in IgAN
patients with TAP of 0.3 to 1.0g/g than in those with TAP of
<0.3g/g.[13] In addition, several studies have shown that CR
conferred better renal outcomes than PR.[17,39] However,
patients with proteinuria <1.0g/day are unlikely to develop
renal events compared with those with proteinuria >1.0g/day,
which can result in a lack of statistical power. Further long-term
studies in large cohorts are required to explore the prognostic
implications of minimal proteinuria. Second, pathologic ﬁndings
were not included in the analyses because different pathologic
classiﬁcation systems are used for the 3 glomerular diseases. Some
pathologic features such as tubulointerstitial ﬁbrosis are strongly
associated with deterioration of kidney function.[40–43] However,
tubulointerstitial lesion is incorporated only in the Oxford
classiﬁcation of IgAN. The Columbia classiﬁcation of FSGS
includes 5 morphologic subtypes, and the pathologic classiﬁca-
tion of MGN mainly describes electron dense deposits in the
glomerular basement membrane. Nevertheless, we separately
analyzed IgAN patients by adding the Oxford classiﬁcation in the
time-varying Cox model, and found that adjustment for
pathologic features did not alter the study results (data not
shown). Third, the 3 glomerular diseases in this study exhibit
slow progression; thus, long-term outcome studies are not
clinically feasible in most research cohorts.[44] Our study is also
limited by the relatively small sample size, the small number of
renal events, and the relatively short follow-up duration.However,
as a glomerular disease cohort, the sample size and follow-up
duration were not inferior to those in the TORONTO registry,[45]
which is the largest cohort of glomerulonephritis worldwide.
Further studies with larger sample sizes and longer follow-up
duration are required to consolidate our results and to clarify the
long-term effect of residual proteinuria on future outcomes in
patients with glomerular disease. Fourth, there was no preset
indication for renal biopsy in our cohort. In most cases, it was
determined by physicians based on the presented signs, symptoms,
and laboratory ﬁndings of patients.However, it is well known that
the prevalence, biopsy practice pattern, treatment, and renal
survival rate vary depending on regions.[46] In addition, in some
glomerulonephritis ethnic difference can impact on disease
progression.[47] This geographic variability and ethnic difference
could not be reﬂected in our observational study.
In conclusion, caution should be exercised when determining
the optimal target level of proteinuria and the risk of renal
progression because the results can differ depending on which
deﬁnition of proteinuria is applied in the analysis. Given the
strengths of TVP, we believe that this is an appropriate method to
identify the effect of continuously changing proteinuria on renal
outcomes over time. By using this method, this study showed that
the risk for renal progression was increased in proportion to the
level of proteinuria during the follow-up period in 3 different
glomerular diseases. Therefore, proteinuria reduction to the
lowest possible level may be helpful to improve renal outcomes in
patients with glomerular diseases.8References
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